Protagenic Therapeutics, Inc.
PTIX- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001022899
In the last 90 days, Protagenic Therapeutics, Inc. insiders filed 7 open-market purchases and 0 sales; 2 institutions reported holding it in 13F filings for Q2 2026, worth $25.4K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Protagenic Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 17 | 16 | −1 |
| Shares | 674.3K | 604.7K | −69.6K (−10.3%) |
| Value | $548.0K | $435.0K | −$113.0K (−20.6%) |
New holders (4)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 14,453 | $10.0K | 0.00% |
| Concorde Asset Management, LLC | 12,418 | $9.00K | 0.01% |
| Morgan Stanley | 1 | $0 | 0.00% |
| CWM, LLC | 3 | $0 | 0.00% |
Sold out (5)
Institutions that held Protagenic Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Oracle Investment Management Inc | 20,000 | $16.0K |
| First Republic Investment Management, Inc. | 17,500 | $14.0K |
| Virtu Financial LLC | 13,045 | $11.0K |
| Citigroup Inc | 250 | $0 |
| Royal Bank of Canada | 1 | $0 |